Cellyan Biotechnology expects 1-for-20 reverse split

Split-adjusted trading in the Class A ordinary shares will continue on Nasdaq under HKPD on October 26, 2026.

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd (HKPD) expects to implement a 1-for-20 reverse stock split, effective at the opening of market on October 26, 2026. The consolidation applies to issued and unissued Class A and Class B ordinary shares. Upon effectiveness, every 20 issued and outstanding ordinary shares will be consolidated into one share; par value will change from $0.001 per share to $0.02 per share.

The company says the split is primarily intended to help it regain compliance with Nasdaq’s minimum bid price requirement. It cautions that there is no assurance it will regain compliance within the applicable compliance period or maintain compliance afterward. Shareholders’ percentage interests will not change, except for adjustments that may result from fractional-share treatment.

Key Figures

Reverse stock split ratio: 1-for-20 Effective date: October 26, 2026 Pre-split par value: $0.001 per share +1 more

4 metrics

Reverse stock split ratio 1-for-20 Expected to take effect October 26, 2026

Effective date October 26, 2026 At the opening of market

Pre-split par value $0.001 per share Before the reverse stock split

Post-split par value $0.02 per share Following the reverse stock split

Key Terms

reverse stock split, split-adjusted basis, fractional shares, minimum bid price requirement

4 terms

reverse stock split financial

"expects to implement a 1-for-20 reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

split-adjusted basis technical

"on a split-adjusted basis"

An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.

fractional shares financial

"Fractional shares resulting from the Reverse Stock Split"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

minimum bid price requirement regulatory

"regain compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Stock Split

1-for-20 reverse split · Effective October 26, 2026

Split Ratio 1-for-20 reverse split

Effective Date October 26, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is HKPD’s reverse stock split ratio and effective date?

Cellyan expects to implement a 1-for-20 reverse stock split effective at the opening of market on October 26, 2026.

Why is HKPD implementing a reverse stock split?

Cellyan says the split is primarily intended to enable it to regain compliance with Nasdaq’s minimum bid price requirement. The company cautions that there is no assurance it will regain compliance within the applicable compliance period or maintain compliance afterward.

How will HKPD handle fractional shares in the reverse split?

Fractional shares resulting from the split will be rounded up to the nearest whole share at a participant level. The company says shareholders’ percentage interests will not change except for adjustments that may result from fractional-share treatment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 08:00 AM EDT Accepted by SEC EDGAR 10/21/2026 - 08:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-42468

CELLYAN BIOTECHNOLOGY CO., LTD
(Translation of registrant’s name into English)

Room B1, 5/F., Well Town Industrial Building,
13 Ko Fai Road, Yau Tong, Kowloon
Hong Kong
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒      Form 40-F ☐

Cellyan Biotechnology Co., Ltd, a Cayman Islands company (the “Company”), furnishes under the cover of Form 6-K the following.

The information contained in this Report on Form 6-K, including Exhibit 99.1 hereto, is hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-296754) and S-8 (Registration No. 333-298301). 

1

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release - Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 21, 2026	CELLYAN BIOTECHNOLOGY CO., LTD
	By:	/s/ Chenyu Liang
		Chenyu Liang
		Director and Chief Executive Officer

3

Exhibit 99.1

Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per share (the “Ordinary Shares”), effective at the opening of market of October 26, 2026 (the “Reverse Stock Split”). Trading in the Class A Ordinary Shares on a split-adjusted basis will continue on Nasdaq on October 26, 2026 under the symbol “HKPD.” The new CUSIP number for the Company’s Ordinary Shares post-Reverse Stock Split is G6365B112.

Upon the effectiveness of the Reverse Stock Split, every twenty issued and outstanding Ordinary Shares will be consolidated into one Ordinary Shares. The Company’s Ordinary Shares have a par value of $0.001 per share prior to the Reverse Stock Split and will have a par value of $0.02 per share following the Reverse Stock Split. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share at a participant level. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares. The Reserves Stock Split was approved by the Company’s board of directors.

The Reverse Stock Split is primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. However, there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq’s continued listing requirement thereafter.

About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting OTC pharmaceutical products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. 

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries please contact:   

Cellyan Biotechnology Co., Ltd

Media Contact: andy@cell-yan.com 

Investor Relations: stella@cell-yan.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE - CELLYAN BIOTECHNOLOGY ANNOUNCES A 1-FOR-20 REVERSE STOCK SPLIT 10.5 KB